(Q38072813)

28 August 2017

1 reference

title

Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer (English)

1 reference

28 August 2017

1 reference

1 reference

Richard D Hall

1

1 reference

28 August 2017

Jhanelle E Gray

series ordinal

2

1 reference

28 August 2017

Alberto A Chiappori

series ordinal

3

1 reference

28 August 2017

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

20

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

22-31

1 reference

28 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000105

10.1177/107327481302000105

21 January 2018

Identifiers

DOI

0 references

1 reference